NEW YORK – Bioinformatics startup Zephyr AI said Wednesday that it has completed an $18.5 million seed funding round. Lerner Group Investments and M-Cor Holdings led the round, with participation from AME Cloud Ventures, BoxGroup, MedStar Health, Verily, and several individual investors.
The Tysons Corner, Virginia-based company, has built a technology platform to aggregate, curate, and analyze multidimensional datasets with artificial intelligence to inform drug discovery and patient care. Zephyr AI draws its data from DNA mutations, copy number variants, gene expression, DNA-protein interactions, drug screening, electronic health records, medical imaging, and other sources.
Zephyr, founded a year ago by investment and incubation firm Red Cell Partners, will apply the new investment to further its goal of supporting precision medicine, particularly in diabetes and cancer care.
"This significant capital raise will help us expand our scope, including curating additional healthcare datasets, refining advanced machine-learning models, and deriving actionable insights for better outcomes in patient care and drug discovery," CEO David Morgan said in a statement.